OncoMatch/Clinical Trials/NCT04998669
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Is NCT04998669 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Loncastuximab tesirine and Rituximab for follicular lymphoma.
Treatment: Loncastuximab tesirine · Rituximab — The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 expression (positive)
Participants who have received previous CD19-directed therapy must have a biopsy which shows CD19 expression after completion of the CD19-directed therapy.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
relapsed or refractory FL previously treated with ≥1 line of systemic therapy
Cannot have received: systemic immunochemotherapy
≥ 6 lines of systemic immunochemotherapy for treatment of FL
Lab requirements
Blood counts
Absolute neutrophil count ≥1000/mm3 (unless due to lymphoma involvement of the bone marrow or spleen). Platelets ≥100,000/mm3 or ≥ 60,000/mm3 in case of bone marrow involvement by lymphoma. Hemoglobin ≥ 10 g/dL or ≥8 g/dL in case of bone marrow involvement by lymphoma.
Kidney function
Creatinine within normal institutional limits, or creatinine clearance ≥30 ml/min/1.7m^2 for patients with creatinine levels above institutional normal (unless due to lymphoma).
Liver function
Total bilirubin < 1.5 x within normal institutional limits (unless due to lymphoma involvement of liver or a known history of Gilbert's disease). GGT/AST/ALT ≤ 2.5 × institutional upper limit of normal.
Patients must have normal organ and marrow function as defined below...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Cancer Specialists and Research Institute · Fort Myers, Florida
- University of Miami · Miami, Florida
- University of Michigan · Ann Arbor, Michigan
- Rutgers Cancer Institute of New Jersey · New Brunswick, New Jersey
- Allegheny Health Network · Pittsburgh, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04998669 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic immunochemotherapy disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages